Last reviewed · How we verify
Clostridum Butyricum Capsule
Clostridum Butyricum Capsule is a Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently FDA-approved.
Clostridum Butyricum Capsule, marketed by Xijing Hospital of Digestive Diseases, holds a niche position in the therapeutic landscape, though specific revenue figures are not disclosed. The drug's key strength lies in its unique mechanism of action, which remains undisclosed but is protected by a key composition patent expiring in 2028. The primary risk to the drug's market position is the lack of detailed clinical trial results and primary indication data, which may limit its adoption and competitive edge.
At a glance
| Generic name | Clostridum Butyricum Capsule |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clostridum Butyricum Capsule CI brief — competitive landscape report
- Clostridum Butyricum Capsule updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI